| scholarly article | Q13442814 |
| P50 | author | Beom Soo Shin | Q48508209 |
| Juergen Bulitta | Q52063271 | ||
| Cornelia Barbara Landersdorfer | Q56769943 | ||
| Rajbharan Yadav | Q57423359 | ||
| Roger L Nation | Q58329346 | ||
| Vanessa E Rees | Q60621528 | ||
| Antonio Oliver | Q87773226 | ||
| Phillip J Bergen | Q104482981 | ||
| John D. Boyce | Q37376174 | ||
| Anton Y. Peleg | Q42220362 | ||
| P2093 | author name string | Tae Hwan Kim | |
| Soon-Ee Cheah | |||
| Kate E Rogers | |||
| P2860 | cites work | Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents | Q24550655 |
| Cystic Fibrosis Lung Infections: Polymicrobial, Complex, and Hard to Treat | Q26771468 | ||
| Evolution of mutation rates in bacteria | Q28238561 | ||
| Lung infections associated with cystic fibrosis | Q30080000 | ||
| The combination of meropenem and levofloxacin is synergistic with respect to both Pseudomonas aeruginosa kill rate and resistance suppression | Q33876615 | ||
| Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units) | Q34111057 | ||
| Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa | Q34228382 | ||
| Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. | Q34307105 | ||
| High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. | Q34508854 | ||
| Stage-specific adaptation of hypermutable Pseudomonas aeruginosa isolates during chronic pulmonary infection in patients with cystic fibrosis | Q34588476 | ||
| Pseudomonas aeruginosa: resistance to the max | Q35084559 | ||
| Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. | Q35134599 | ||
| Two mechanisms of killing of Pseudomonas aeruginosa by tobramycin assessed at multiple inocula via mechanism-based modeling. | Q35168882 | ||
| Novel approach to optimize synergistic carbapenem-aminoglycoside combinations against carbapenem-resistant Acinetobacter baumannii | Q35168931 | ||
| A survey of once-daily dosage tobramycin therapy in patients with cystic fibrosis | Q46069692 | ||
| Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis | Q46172261 | ||
| Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair | Q46617407 | ||
| Contribution of clonal dissemination and selection of mutants during therapy to Pseudomonas aeruginosa antimicrobial resistance in an intensive care unit setting | Q46744991 | ||
| Hypermutation as a Factor Contributing to the Acquisition of Antimicrobial Resistance | Q79162727 | ||
| Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis | Q84219534 | ||
| The role of mutators in the emergence of antibiotic-resistant bacteria | Q35177659 | ||
| Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis | Q35557791 | ||
| Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections | Q35759054 | ||
| Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model | Q35820123 | ||
| Aminoglycoside resistance in Pseudomonas aeruginosa | Q36021296 | ||
| National survey of extended-interval aminoglycoside dosing in pediatric cystic fibrosis pulmonary exacerbations | Q36063806 | ||
| Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. | Q36213685 | ||
| Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. | Q36232237 | ||
| Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation | Q36295397 | ||
| Pharmacokinetic and experimental data on beta-lactam antibiotics in the treatment of patients | Q36605659 | ||
| A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples | Q36780059 | ||
| Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design | Q36785827 | ||
| Continuous infusion of beta-lactams. | Q36924963 | ||
| Association between hypermutator phenotype, clinical variables, mucoid phenotype, and antimicrobial resistance in Pseudomonas aeruginosa | Q36933558 | ||
| Optimization of Synergistic Combination Regimens against Carbapenem- and Aminoglycoside-Resistant Clinical Pseudomonas aeruginosa Isolates via Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling | Q37538623 | ||
| Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations | Q37591703 | ||
| Hypermutation and the preexistence of antibiotic-resistant Pseudomonas aeruginosa mutants: implications for susceptibility testing and treatment of chronic infections | Q37598703 | ||
| Mutators in cystic fibrosis chronic lung infection: Prevalence, mechanisms, and consequences for antimicrobial therapy | Q37788421 | ||
| Bacterial hypermutation: clinical implications | Q37847007 | ||
| Antibiotic treatment of CF lung disease: from bench to bedside | Q37887170 | ||
| Adaptation of Pseudomonas aeruginosa to the cystic fibrosis airway: an evolutionary perspective | Q38059441 | ||
| Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model | Q40306198 | ||
| Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases | Q40325943 | ||
| Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patien | Q40470332 | ||
| Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies | Q40477935 | ||
| Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies | Q40587067 | ||
| Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling. | Q40657200 | ||
| Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis | Q41063056 | ||
| The ADMIN-ICU survey: a survey on antimicrobial dosing and monitoring in ICUs | Q41110594 | ||
| Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation | Q41366386 | ||
| The pharmacology of meropenem, a new carbapenem antibiotic | Q41451214 | ||
| Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections | Q41974061 | ||
| Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. | Q41987074 | ||
| Performance and robustness of the Monte Carlo importance sampling algorithm using parallelized S-ADAPT for basic and complex mechanistic models. | Q42143847 | ||
| Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models | Q42169493 | ||
| Resistance suppression by high-intensity, short-duration aminoglycoside exposure against hypermutable and non-hypermutable Pseudomonas aeruginosa | Q42717931 | ||
| Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis | Q42790860 | ||
| Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa | Q43215544 | ||
| A survey of the utilization of anti-pseudomonal beta-lactam therapy in cystic fibrosis patients | Q43425473 | ||
| Pharmacokinetics of high-dose meropenem in adult cystic fibrosis patients | Q43578365 | ||
| Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? | Q43874264 | ||
| Mathematical modelling response of Pseudomonas aeruginosa to meropenem | Q43967705 | ||
| Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. | Q46034494 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Pseudomonas aeruginosa | Q31856 |
| meropenem | Q421670 | ||
| P577 | publication date | 2018-03-27 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Optimization of a Meropenem-Tobramycin Combination Dosage Regimen against Hypermutable and Nonhypermutable Pseudomonas aeruginosa via Mechanism-Based Modeling and the Hollow-Fiber Infection Model | |
| P478 | volume | 62 |
| Q57240383 | Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis |
| Q92127147 | Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans |
| Q58164270 | Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients |
| Q57169588 | Meropenem combined with ciprofloxacin combats hypermutable from respiratory infections of cystic fibrosis patients |
| Q92620539 | Pharmacodynamic Drug-Drug Interactions |
| Q92707838 | Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model |
Search more.